BioSpace News Archive

The Insight Partners published latest research report on “Molecular Biology Enzymes, Kits, and Reagents Market Growth Report, Size, Share, Trends & Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Application, and End User

Histologics LLC manufactures Kylon® medical fabric sterile brush devices which use gentle friction to biopsy the outer cervix and endocervical canal.

PharmAla Biotech Holdings Inc., a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules and its distribution partner, CCrest Laboratories have received an authorization to provide a number of its LaNeo MDMA capsules to a Canadian physician for treatment of a patient under Health Canada’s Special Access Program.

Horizon Therapeutics plc issued the following statement in response to the FTC’s complaint seeking to block Amgen’s proposed acquisition of the Company.

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Illumina Inc., a global leader in DNA sequencing and array-based technologies, recognized the progress and impact of genomic technologies on pathogen preparedness and response.

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced plans to accelerate the expansion of the Newton™ Knee to the Asia-Pacific region.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”) today reported financial information for the first quarter of 2023, including its cash, cash equivalents and revenues, and provided a corporate update.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2023.